<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399592</url>
  </required_header>
  <id_info>
    <org_study_id>Toco-Ovar</org_study_id>
    <nct_id>NCT02399592</nct_id>
  </id_info>
  <brief_title>Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer</brief_title>
  <acronym>Toco-Ovar</acronym>
  <official_title>Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to to investigate the effect of tocotrienol as a nutritional&#xD;
      supplement in combination with bevacizumab in patients with advanced ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">July 2019</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fraction of patients without progression after six months of treatment</measure>
    <time_frame>6 months after start of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Bevacizumab and Tocotrienol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>10 mg/kg q3w</description>
    <arm_group_label>Bevacizumab and Tocotrienol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocotrinol</intervention_name>
    <description>300 mg tid</description>
    <arm_group_label>Bevacizumab and Tocotrienol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed epithelial, primary fallopian or primary peritoneal cancer.&#xD;
&#xD;
          -  Prior treatment with at least two different cytostatic regimens including platinum.&#xD;
&#xD;
          -  Progression on previous treatment.&#xD;
&#xD;
          -  Measurable disease by RECIST 1.1 or evaluable by GCIG CA-125 criteria.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Performance stage 0-2.&#xD;
&#xD;
          -  Adequate bone marrow function, liver function, and renal function (within 7 days prior&#xD;
             to inclusion):&#xD;
&#xD;
               -  WBC ≥ 3.0 * 10^9/l or neutrophils (ANC) ≥ 1.5 * 109/l&#xD;
&#xD;
               -  Platelet count ≥ 100 * 10^9/l&#xD;
&#xD;
               -  Hemoglobin ≥ 6 mmol/l&#xD;
&#xD;
               -  Serum bilirubin &lt; 2.0 * ULN&#xD;
&#xD;
               -  Serum transaminase ≤ 2.5 * ULN&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 ULN&#xD;
&#xD;
          -  Urine dipstick for protein &lt;2+. If the dipstick shows protein ≥2+ 24 hour urine&#xD;
             testing must be made with protein contents &lt; 1 g.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other malignant diseases within 5 years prior to inclusion in the study, except&#xD;
             curatively treated basal cell or squamous cell carcinoma of the skin and other types&#xD;
             of cancer with minimal risk of recurrence.&#xD;
&#xD;
          -  Other experimental therapy or participation in another clinical trial within 28 days&#xD;
             prior to treatment initiation.&#xD;
&#xD;
          -  Underlying medical disease not adequately treated (diabetes, cardiac disease).&#xD;
&#xD;
          -  Uncontrolled hypertension (BT &gt;150/100 despite antihypertensive treatment).&#xD;
&#xD;
          -  Surgery, incl. open biopsy, within 4 weeks prior to first dose of bevacizumab.&#xD;
&#xD;
          -  Non-healing wounds or fractures.&#xD;
&#xD;
          -  Cerebral vascular attack, transient ischemic attack or subarachnoidal hemorhage within&#xD;
             6 months before start of treatment.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease, including:&#xD;
&#xD;
               -  Myocardial infarction or unstable angina within 6 months before start of&#xD;
                  treatment&#xD;
&#xD;
               -  New York heart Association (NYHA) class ≥ 2&#xD;
&#xD;
               -  Poorly controlled cardiac arrhythmia despite medication&#xD;
&#xD;
               -  Periferal vascular disease grade ≥ 3&#xD;
&#xD;
          -  Allergy to the active substance or any of the auxiliary agents&#xD;
&#xD;
          -  Bleeding tumor&#xD;
&#xD;
          -  Pregnant or breast-feeding patients. For fertile women a negative pregnancy test at&#xD;
             screening is mandatory.&#xD;
&#xD;
          -  Fertile patients not willing to use effective methods of contraception during&#xD;
             treatment and for 6 months after the end of treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Jakobsen, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology, Vejle Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 20, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platinum resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

